Clinical Trial Update: OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) [Phase 3]

View source ↗

Summary

A Phase 3 trial of OPT-302 in combination with aflibercept for neovascular age-related macular degeneration was terminated; results have been posted as of 2025-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)
• OPT-302

Snippet

Sponsor: Opthea Limited | Conditions: Neovascular Age-related Macular Degeneration | Phase 3 | Status: TERMINATED | Results posted: 2025-08-05